公开(公告)号：US20230391869A1

公开(公告)日：2023-12-07

申请号：US18316564

申请日：2023-05-12

Applicant: ACTICOR BIOTECH ,  UNIVERSITÉ PARIS CITÉ ,  UNIVERSITÉ PARIS-XIII ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE PARIS-SACLAY

Inventor： Philippe BILLIALD ,  Martine JANDROT-PERRUS ,  Gilles AVENARD

IPC: C07K16/28 ,  A61K9/00

CPC classification number: C07K16/2803 ,  A61K9/0019 ,  A61K2039/505

Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.

公开(公告)号：US20230384312A1

公开(公告)日：2023-11-30

申请号：US18249830

申请日：2021-10-22

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS ,  UNIVERSITE D'ANGERS ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

Inventor： Maria del Carmen MARTINEZ ,  Pierre BIGOT ,  Luisa VERGORI

IPC: G01N33/574

CPC classification number: G01N33/57438 ,  G01N33/57484 ,  G01N2333/988

Abstract: A method of predicting the risk of recurrence in a subject undergoing treatment for, or having undergone treatment for, clear cell renal cell carcinoma (ccRCC), by comparing the level of extracellular vesicles, preferably microvesicles, expressing carbonic anhydrase 9 (CA9+ MVs) in a sample from the subject with a reference level. Also, a method of diagnosing ccRCC or identifying a risk of developing ccRCC, by comparing the level of CA9+ MVs in a sample from the subject with a reference level.

公开(公告)号：US20230381224A1

公开(公告)日：2023-11-30

申请号：US18338314

申请日：2023-06-20

Applicant: Institut Pasteur de Lille ,  Institut National de la Santé et de la Recherche Médicale (INSERM)

Inventor： Luis Solans ,  Camille Locht ,  Anne Tsicopoulos ,  Saliha Ait-Yahia Sendid

IPC: A61K35/00 ,  C07K14/235 ,  A61K9/00 ,  A61K35/74 ,  A61K39/02

CPC classification number: A61K35/00 ,  C07K14/235 ,  A61K9/007 ,  A61K35/74 ,  A61K39/099 ,  A61K2039/10

Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.

公开(公告)号：US11821972B2

公开(公告)日：2023-11-21

申请号：US17702212

申请日：2022-03-23

Applicant: Siemens Healthcare GmbH ,  Centre National de la Recherche Scientifique (CNRS) ,  Institut National de La Sante et de la Recherche Medicale (INSERM) ,  King's College London ,  Department of Health and Human Services ,  UNIV PARIS XIII PARIS-NORD VILLETANEUSE ,  Universite de Paris

Inventor： Omar Darwish ,  Radhouene Neji ,  Ahmed M. Gharib ,  Ralph Sinkus

IPC: G01R33/30 ,  G01R33/563 ,  H02P8/22 ,  H02P8/08

CPC classification number: G01R33/56358 ,  G01R33/30 ,  H02P8/08 ,  H02P8/22

Abstract: The present disclosure is directed to techniques for synchronizing a rotational eccentric mass of a gravitational transducer used for a magnetic resonance elastography acquisition with a corresponding magnetic resonance elastography scan carried out by a magnetic resonance imaging system, wherein the rotation of the eccentric mass is driven by a shaft. The method includes starting the rotation of the eccentric mass at a set vibration frequency and the magnetic resonance elastography scan at a set acquisition frequency; determining the rotational position of the shaft; defining the rotational position as first reference position; calculating further reference positions. At the start time of each subsequent acquisition period, determining the current rotational position of the shaft; comparing the determined current rotational position with the theoretically expected reference position and decreasing or increasing the rotational speed of the rotational eccentric mass based on the comparison.

公开(公告)号：US11820726B2

公开(公告)日：2023-11-21

申请号：US16927840

申请日：2020-07-13

Applicant: University of Central Florida Research Foundation, Inc. ,  INSERM TRANSFERT

Inventor： Otto Phanstiel, IV ,  Jean-Michel Brunel

IPC: C07C211/17 ,  A61K45/06 ,  A61K31/132 ,  A61P31/04 ,  A61K31/7048 ,  A61K31/165 ,  A61K31/32 ,  C07D225/02 ,  A61K31/546 ,  A61K31/65 ,  A61K31/16

CPC classification number: C07C211/17 ,  A61K31/132 ,  A61K31/16 ,  A61K31/165 ,  A61K31/32 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7048 ,  A61K45/06 ,  A61P31/04 ,  C07D225/02 ,  C07C2601/18 ,  Y02A50/30 ,  A61K31/16 ,  A61K2300/00 ,  A61K31/32 ,  A61K2300/00 ,  A61K31/65 ,  A61K2300/00 ,  A61K31/165 ,  A61K2300/00 ,  A61K31/546 ,  A61K2300/00 ,  A61K31/7048 ,  A61K2300/00

Abstract: Motuporamine agents having antimicrobial activity and uses thereof.

公开(公告)号：US20230365964A1

公开(公告)日：2023-11-16

申请号：US18044698

申请日：2021-09-09

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÈ ET DE LA RECHERCH MÉDICALE ,  UNIVERSITÉ DE LIMOGES ,  CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE LIMOGES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Laurent DELPY ,  Anne MARCHALOT ,  Jean FEUILLARD ,  Francois BOYER ,  Nathalie FAUMONT

IPC: C12N15/113

CPC classification number: C12N15/113 ,  C12N2310/11 ,  C12N2320/33

Abstract: The need to identify new therapeutic approaches in the treatment of cancers of the B lymphoid lineage is crucial. Here, the inventors provide evidence for efficient knockdown of c-REL and RELA expression after treatment with splice switching antisense oligonucleotides (SSO) inducing exon skipping and reading frameshift. For instance, treatments with morpholino SSO targeting c-REL exon 2 donor splice site or RELA exon 5 acceptor splice site elicited very efficient knockdown in diffuse large B cell lymphoma (DLBCL) cell lines and antibody-secreting cells derived from primary human B cells. Consistent with the clinical relevance of c-REL activation in DLBCL, treatment with c-REL SSO induced major alterations in NF-κB and TNF signalling pathways and strongly decreased cell viability. Altogether, SSO-mediated knockdown is a powerful approach to inhibit transiently the expression of a NF-κB component in B-lineage cells that should open new avenues for cancer treatments. Accordingly, the present invention relates to the use of splice switching oligonucleotides for exon skipping-mediated knockdown of a NF-κB component in B cells.

公开(公告)号：US20230330440A1

公开(公告)日：2023-10-19

申请号：US18044645

申请日：2021-09-09

Applicant: SORBONNE UNIVERSITE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

Inventor： Serge PICAUD ,  Sara CADONI ,  José-Alain SAHEL ,  Mickaël TANTER ,  Charlie DEMENE

IPC: A61N7/00 ,  C12N15/86

CPC classification number: A61N7/00 ,  C12N15/86 ,  A61N2007/0026 ,  C12N2750/14143 ,  A61N2007/0095

Abstract: Devices and methods for reversibly stimulating neuronal cells in a subject. The devices include a module for generating ultrasounds at 4 MHz or more to stimulate neuronal cells expressing mechanosensitive channels with the ultrasounds. The methods include expressing mechanosensitive channels into neuronal cells and exposing the cells to ultrasounds at 4 MHz or more. Also, the use of the methods or devices for visual restoration in a subject.

公开(公告)号：US20230323366A1

公开(公告)日：2023-10-12

申请号：US18014977

申请日：2021-07-09

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITÉ D’AIX-MARSEILLE ,  UNIVERSITÉ DE BORDEAUS ,  REGENXBIO INC. ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Céline BOILEAU ,  Valérie CREPEL ,  Séverine DEFORGES ,  Julie MASANTE ,  Christophe NULLE ,  Angélique PERET ,  Olivier DANOS ,  Andrew MERCER

IPC: C12N15/113 ,  A61P25/08 ,  C12N15/86

CPC classification number: C12N15/1138 ,  A61P25/08 ,  C12N15/86 ,  C12N2310/11 ,  C12N2310/531 ,  C12N2750/14143

Abstract: The present disclosure relates to gene therapy targeting GluK2 subunit that can be used to inhibit epileptiform discharges. Short interfering RNA sequences against the human Grik2 gene sequence are described which are efficient in decreasing the expression of GluK2-containing KARs in neurons engineered to express the equivalent shRNA or miRNA. Using a tissue culture model of TLE, the examples remarkably demonstrate that viral expression of shRNA or miRNA inhibits the frequency of epileptiform discharges. Therefore, RNA therapeutics aimed at decreasing the expression of GluK2-containing KARs in neurons can remarkably prevent spontaneous epileptiform discharges in TLE. In particular, the present disclosure relates to a recombinant antisense oligonucleotide that targets a Grik2 mRNA. The present disclosure also relates to a method for treating epilepsy in a subject in need thereof, wherein the method comprises: administering an effective amount of a vector comprising an oligonucleotide encoding an inhibitory RNA that binds (e.g., hybridizes) specifically to Grik2 mRNA and inhibits expression of Grik2 in the subject.

公开(公告)号：US20230323299A1

公开(公告)日：2023-10-12

申请号：US18040363

申请日：2021-08-02

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCH MÉDICALE) ,  MEDECIN ET INNOVATION ,  UNIVERSITÉ PARIS CITÉ

Inventor： Hélène LE BUANEC ,  Daniel ZAGURY

IPC: C12N5/0783

CPC classification number: C12N5/0637 ,  C12N2501/01 ,  C12N2501/15 ,  C12N2501/2302

Abstract: Natural Treg (nTreg) can potentially suppress cell immune response. Consequently, these CD4+ CD25+ CD127low Foxp3+ T cells are used in adoptive therapy against autoimmune and GVH disease. One difficulty is the varying functional properties depending on the microenvironment that may cause the loss of their suppressive activity and promote TH17- induced inflammatory effects. By ex vivo transdetermination of CD31 TH0 cells, the inventors established and expanded a Foxp3 regulatory T cell population (CD31d-Treg cells) functionally committed to exert a permanent Ag-specific regulatory activity whichever the microenvironmental conditions are. By contrast to nTreg cells, CD31d-Treg cells do not express the IL1 Receptor whose activation is required for IL-17 production. Accordingly, the present invention relates to a population of CD31d-Treg cells functionally committed to exert a regulatory activity and their use for Treg-based adoptive therapy.

公开(公告)号：US20230322952A1

公开(公告)日：2023-10-12

申请号：US17791549

申请日：2021-01-08

Applicant: BIOMUNEX PHARMACEUTICALS ,  INSTITUT CURIE ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Inventor： OLIVIER LANTZ ,  SEBASTIAN AMIGORENA ,  MICHAEL SAITAKIS ,  MAUDE GUILLOT-DELOST ,  EUGENE ZHUKOVSKY ,  PIERRE-EMMANUEL GERARD ,  MUSTAPHA FAROUDI

IPC: C07K16/46 ,  A61P35/00

CPC classification number: C07K16/468 ,  A61P35/00 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/522 ,  C07K2317/565

Abstract: The invention provides a multispecific molecule capable of simultaneous binding to a Mucosal Associated Invariant T (MAIT) cell and a tumor cell, which multispecific molecule comprises at least one domain that specifically binds a Vα7.2 T cell receptor (TCR) and at least one domain that specifically binds a tumor associated antigen (TAA).